Company intelligence / Profile preview
DiObex, Inc.
San Francisco, California, United Statesdiobex.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
DiObex had two lead drug candidates in mid-stage clinical development. DIO-901 (very low dose glucagon) was being developed for preventing insulin-induced hypoglycemia in diabetes patients and had received Fast Track status from the FDA. DIO-902 (levdexketoconazole), a cortisol synthesis inhibitor, was in development for type 2 diabetes and diabetic nephropathy. The company completed Phase 2a clinical trials and was planning to initiate a 16-week Phase 2b dose-ranging study in patients with type 2 diabetes by mid-2007.[1][4]
- Therapeutic areas
- EndocrinologyMetabolic DisordersNephrology
- Modalities
- Small moleculespeptides
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on DiObex, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DiObex, Inc..